The US Food and Drug Administration issued draft guidance that could lower the bar for biosimilar development by allowing data from comparator products sourced outside the United States and reducing certain clinical testing requirements. The proposal aims to cut development costs and accelerate approvals, addressing high biologic prices and encouraging competition. The FDA estimates the change could halve development costs in some cases and expand biosimilar availability, particularly in oncology and chronic disease areas dominated by high‑cost biologics. The industry will now assess the draft’s specifics, foreign regulatory alignment, and how payors and providers respond to a broader entry of biosimilars into formularies.